Recombinant Human IL-33 Instruction

General description

Interleukin-33 is a dual-function cytokine that serves as a nuclear transcriptional regulator in healthy cells and as an alarmin released during cellular damage to activate type 2 immunity, mast cells, and ILC2s. It is a critical mediator of allergic inflammation, tissue fibrosis, and helminth immunity. Recombinant Human IL-33 Protein (Y12821H) is expressed from E. coli cells. It contains AA Ser 112 - Thr 270 (Accession # NP_001186569.1), and is widely used in advanced cell culture, allergy research, and tissue inflammation modeling.

Application

· Type 2 Immunity and Allergic Inflammation — Drives Th2 differentiation, ILC2 activation, and IgE class switching.

· Mast Cell and Basophil Activation — Induces degranulation, cytokine release, and tissue inflammatory responses.

· Airway Hyperresponsiveness and Asthma Modeling — Promotes eosinophilic inflammation and mucus hypersecretion.

· Tissue Fibrosis and Wound Healing Studies — Investigates IL-33-driven fibroblast activation and collagen deposition.

· Serum-Free Culture Systems — Suitable for chemically defined and xeno-free cell culture media.

Product Specifications

Stability and Reconstitution

36 months at -20°C to -80°C in lyophilized state;

6 months at -20°C to -80°C under sterile conditions after reconstitution;

7-10 days at 2°C to 8°C under sterile conditions after reconstitution;

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

It is recommended to redissolve in sterile deionized water.

Backgroud

Interleukin-33, also known as IL-33 or NF-HEV, is a unique member of the IL-1 cytokine family that exhibits dual localization and function. In the nucleus of healthy endothelial and epithelial cells, IL-33 functions as a transcriptional regulator through its chromatin-binding domain. Upon cellular damage, necrosis, or mechanical stress, IL-33 is released into the extracellular space where it acts as an alarmin, activating immune cells through the ST2/IL-1RAcP receptor complex. This receptor is expressed on Th2 cells, ILC2s, mast cells, basophils, eosinophils, and alternatively activated macrophages, creating a cellular network dedicated to type 2 immune responses. IL-33 activates MyD88-dependent NF-κB and MAPK signaling, driving the production of IL-5, IL-13, and amphiregulin that promote eosinophilia, mucus production, tissue repair, and fibrosis. In helminth infections, IL-33 is essential for protective type 2 immunity and worm expulsion. However, dysregulated IL-33 signaling drives allergic asthma, atopic dermatitis, eosinophilic esophagitis, and idiopathic pulmonary fibrosis. The biological activity of IL-33 is regulated by caspase-1 and caspase-3 cleavage during apoptosis, which inactivates the cytokine and prevents inappropriate immune activation during programmed cell death. EastMabBio's IL-33 enables researchers to model type 2 immune responses, study alarmin biology, investigate allergic disease mechanisms, and explore the therapeutic potential of ST2 blockade in fibrotic diseases.

Q&A

Q1:  What is IL-33 mainly used for?

IL-33 is primarily used for type 2 immunity research, allergic inflammation modeling, mast cell activation studies, and tissue fibrosis investigations.

Q2: Is this IL-33 suitable for serum-free culture systems?

Yes. EastMabBio recombinant IL-33 is compatible with serum-free, xeno-free, and chemically defined media systems.

Q3: How should recombinant IL-33 be stored?

Lyophilized protein should be stored at -20°C or below. After reconstitution, aliquot and avoid repeated freeze-thaw cycles.

Q4: What shipping conditions are used?

Products are shipped on dry ice with validated cold-chain packaging to maintain stability during international transportation.

Q5: Do you provide QC documents?

Yes. COA, MSDS, TSE-BSE statements, endotoxin reports, bioactivity data, and additional QC documentation are available upon request.